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To identify key regulators of human brain tumor maintenance and initiation, we performed multiple genome-wide
RNAi screens in patient-derived glioblastoma multiforme (GBM) stem cells (GSCs). These screens identified the
plant homeodomain (PHD)-finger domain protein PHF5A as differentially required for GSC expansion, as
compared with untransformed neural stem cells (NSCs) and fibroblasts. Given PHF5A’s known involvement in
facilitating interactions between the U2 snRNP complex and ATP-dependent helicases, we examined cancer-
specific roles in RNA splicing. We found that in GSCs, but not untransformed controls, PHF5A facilitates
recognition of exons with unusual C-rich 39 splice sites in thousands of essential genes. PHF5A knockdown in
GSCs, but not untransformed NSCs, astrocytes, or fibroblasts, inhibited splicing of these genes, leading to cell
cycle arrest and loss of viability. Notably, pharmacologic inhibition of U2 snRNP activity phenocopied PHF5A
knockdown in GSCs and also in NSCs or fibroblasts overexpressing MYC. Furthermore, PHF5A inhibition
compromised GSC tumor formation in vivo and inhibited growth of established GBM patient-derived xenograft
tumors. Our results demonstrate a novel viability requirement for PHF5A to maintain proper exon recognition in
brain tumor-initiating cells and may provide new inroads for novel anti-GBM therapeutic strategies.
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Malignant glioma is the most common and lethal form
of brain cancer. Glioblastoma multiforme (GBM) is the
most invasive and aggressive grade of glioma and is no-
toriously drug- and radiation-resistant. There are cur-
rently no highly effective therapies against GBM, and
with standard of care treatments, including surgery,
radiation, and chemotherapy, ;90% of adult patients
die within 2 yr of diagnosis (Latera and Brem 2002; Central
Brain Tumor Registry of the United States (CBTRUS),
http://www.cbtrus.org), underscoring the need for novel
therapeutic targets. The hierarchical organization of adult
and pediatric brain tumors suggests a cancer stem cell
origin (Hemmati et al. 2003; Singh et al. 2003, 2004; Galli
et al. 2004). Consistent with this idea, tumor-initiating
GBM stem cells (GSCs) isolated from patients retain the
developmental potential and specific genetic alterations
found in the original tumor (Hemmati et al. 2003; Singh
et al. 2003; Lee et al. 2006; Pollard et al. 2009).
When isolated under serum-free monolayer condi-
tions, GSCs can retain tumor-initiating potential and
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tumor-specific genetic and epigenetic signatures over
extended outgrowth periods (Lee et al. 2006; Pollard
et al. 2009). In addition, they have been shown to recreate
tumor cellular hierarchies when implanted into the
cortex of immunocompromised mice (Lee et al. 2006;
Pollard et al. 2009). Furthermore, GSC isolates also retain
expression of neural progenitor molecular networks,
which may contribute to the aggressive behavior of GBM
tumors through enhancing self-renewal or developmental
programs (Mangiola et al. 2007; Stiles and Rowitch 2008;
Gangemi et al. 2009), DNA repair pathways (Bao et al.
2006a), angiogenesis (Bao et al. 2006b; Cheng et al. 2013),
and/or invasiveness (Liu et al. 2009).
Recently, in order to identify new candidate therapeu-
tic targets for GBM, we combined functional genetics and
GBM network modeling to identify human kinases re-
quired for the expansion of GSCs but dispensable to
proliferating neural stem cells (NSCs) (Ding et al. 2013).
This approach yielded BUB1B/BUBR1, a critical mitotic
spindle kinase, as a GBM-lethal gene. Our studies revealed
that certain GBM tumors have an added requirement for
a nonessential BUB1B activity to suppress lethal conse-
quences of altered kinetochore function (Ding et al. 2013).
Thus, these results demonstrated that patient-derived
GSCs can be used to identify cancer- and patient-specific
molecular vulnerabilities for GBM that are not observed in
tissue-appropriate or other nontransformed control cells
(e.g., NSCs and astroyctes).
Here, we expanded our search for GBM-lethal genes by
performing genome-wide RNAi screens in multiple GSC
patient isolates and NSCs to identify genes differentially
required for GSC expansion. These studies revealed that
the plant homeodomain (PHD)-finger domain protein
PHF5A was differentially required for expansion and via-
bility of multiple GSC isolates. Molecular studies demon-
strated that GSCs have a novel requirement for PHF5A
activity to facilitate recognition of exonswith distinctive 39
splice sites. PHF5A knockdown resulted in splicing defects
in thousands of essential genes, a subset of which are pre-
dicted to affect cell division and growth (e.g., CDC20 and
RAF1). Cell-based assays revealed that PHF5A/U2snRNP
perturbation causes G2/M arrest in GSCs both in vitro and
during cell growth in established patient-derived tumors.
Importantly, sensitivity to U2snRNP perturbation could be
recreated in NSCs and fibroblasts overexpressing MYC.
Although MYC is not frequency amplified in GBM, MYC
is coordinately activated by mutations in p53 and PTEN,
two of the most common mutations in GBM (Zheng et al.
2008b), and is also essential for human GSC self-renewal
(Wang et al. 2008). Our results demonstrate an unexpected
role for PHF5A in maintaining proper exon recognition in
GSCs, which is critical for growth and maintenance of
patient-derived tumors.
Results
Functional genetic screens identify PHF5A
as differentially required for GSC expansion
To identify genes necessary for the growth and survival of
GSCs but likely dispensable to noncancerous neural cells
and tissues, we performed functional genetic shRNA
screens that targeted 1086 nucleic acid-binding factors
in both primary GSC tumor isolates and human fetal
NSC-CB660 cells. For these screens, we assayed genes
required for GSC and NSC in vitro expansion in serum-
free monolayer culture (Fig. 1A; Pollard et al. 2009; Ding
et al. 2013).
Cells were infected with pools of shRNAs (Paddison
et al. 2004; Luo et al. 2009) and expanded in triplicate
screening populations under normal conditions for 21 d.
Comparisons of shRNA representation in GSCs or NSCs
over time using microarrays or deep sequencing revealed
a subset of shRNAs that became significantly under- or
overrepresented during expansion. Candidate GSC-specific
lethal genes were defined as those shRNAs that were
significantly underrepresented in GSC cultures relative
to NSC control cultures.
The nucleic acid-binding gene screen, which was
performed in a single GBM isolate (G166 cells) along
with NSC controls, yielded 27 genes as candidate GBM-
lethal hits. Retests of each screen hit were performed
using multiple single-shRNA viral clones. Seven genes
(26% of candidates) met our validation criteria of two
or more single hairpin clones that produced a growth ratio
of <0.65 in GSCs cells compared with NSCs with a
P-value <0.05 after 7 d of outgrowth (Fig. 1B; Supplemen-
tal Fig. 1a). Significantly, knockdown of the gene PHF5A
was strongly indicated as the top hit affecting in vitro
expansion of GSC-G166 cells (Fig. 1B; Supplemental Fig.
1a). To ensure that the results were applicable to other
GBM tumors and that hits would score similarly when
comparing the entire genome, we also performed ge-
nome-wide shRNA screens inmultiple GSC isolates from
three different GBM patients that represented two de-
velopmental subtypes (G166, mesenchymal; 0131, mes-
enchymal; 0827, proneural), again in triplicate with NSCs
as controls. This approach yielded GSC screen hits that
were mainly isolate-specific, likely owing to different
tumor backgrounds and heterogeneity in cell popula-
tions during expansion (Fig. 1C). However, there were 17
candidate lethal genes shared by each GSC isolate that
did not score in NSCs; PHF5A was among these genes
(Fig. 1C).
It should be noted that identifying genes that, when
inhibited, affect growth of GSCs more than NSCs is
unusual. We found that most perturbations in pathways
required for cell growth or cell cycle progression (e.g.,
PI3K pathway, Aurora A and B kinases, heat-shock pro-
tein 90, and the microtubule motor protein KIF11/Eg5)
(Ding et al. 2013; data not shown) either show no dif-
ferential effect between NSCs and GSCs or affect NSCs
more than GSCs.
PHF5A is a highly conserved PHD-zinc finger domain
protein that facilitates interactions between the U2 snRNP
complex and DNA/RNA helicases (Rzymski et al. 2008).
PHF5A may also bind to chromatin through its PHD
domain (Trappe et al. 2002), which, in other PHD family
members, can facilitate interactions with specific histone
marks on chromatin-bound nucleosomes (Mellor 2006;
Musselman and Kutateladze 2009). Consistent with this
Novel requirement for PHF5A in brain tumors
GENES & DEVELOPMENT 1033
Figure 1. Functional genetic screens identify PHF5A as differentially required for GSC expansion. (A) The shRNA screening approach
used to initially identify PHF5A as differentially required for GSC expansion. Pooled viruses targeting nucleic acid-binding factors were
used in outgrowth screens in human GSC-G166 and NSC-CB660 cells. Candidate genes differentially required for GSC expansion over
21 d of outgrowth were identified through hybridization of viral DNA barcodes to custom microarrays. (B) Average differential between
GSCs and NSCs for shRNA clones targeting candidate screen hits by in vitro competition assay. Cells infected with single shRNA
clones (GFP+) were mixed with uninfected cells and outgrown for 10 d, and the change in GFP+ cells in each culture was quantified by
FACS analysis. (C) Our genome-wide shRNA screening strategy used in NSC-CB660 and three primary GSC isolates. Viral shRNA
pools targeting ;19,000 human genes were infected into cells prior to 21 d of outgrowth in vitro. The change in viral shRNA
representation in each cell population was quantified by sequencing. Gene targets statistically underrepresented at the end of the
culture period are shown. (D) Viability of NSCs and five GSC isolates infected with three independent shRNA viral clones targeting
PHF5A. (M) Mesenchymal subgroup; (PN) proneural subgroup; (*) P-value < 0.002 vs. CB660. (E) Western blot analysis of PHF5A protein
expression in NSCs and GSCs after PHF5A knockdown. (F) Images of GSC-0131 cell clones expressing an inducible shRNA
construct targeting the endogenous 39 UTR of PHF5A, with or without rescue by exogenous expression of full length PHF5A. Bar,
50 mm. (G) PHF5A was immunoprecipitated from cellular lysates, and associated binding proteins were analyzed by mass spectrometry.
The gene ontology (GO) categories most enriched among PHF5A-bound proteins are presented. See also Supplemental Figure S1.
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latter notion, PHF5A protein was found to be an enhancer
of estrogen-mediated transcription of the Connexin 43
gene (Oltra et al. 2003). PHF5A has also been characterized
as a member of the SF3b component of the U2 snRNP
splicing complex (Will et al. 2002). Since PHF5A was a
highly reproducible GSC-specific screen hit, yet nothing
is known about a cancer-specific role for PHF5A, we
further pursued it as a GBM-lethal target.
PHF5A is differentially required for GSC in vitro
expansion
To further confirm differential effects of PHF5A knock-
down, we performed short-term outgrowth assays in five
primary GSC cultures using multiple shRNAs. In each
case, PHF5A knockdown showed a strong, GSC-specific
loss of viability (Fig. 1D). Next, we examined the effects
of PHF5A knockdown on SSEA1+ GSC subpopulations,
which are enriched for tumor-initiating cell activity (Son
et al. 2009). In the three different GSC isolates examined,
PHF5A knockdown compromised outgrowth of SSEA1+
populations over the course of several weeks (Supple-
mental Fig. S1b). This indicates that PHF5A suppression
blocks gross expansion of GSC isolates, including both
the bulk cell population and tumor-initiating GSC sub-
populations.
GSCs and NSCs express PHF5A at relatively similar
levels, and knockdown is equivalently effective in each
cell type at both the RNA and protein levels (Fig. 1E;
Supplemental Fig. S1c), indicating that the lack of phe-
notype in NSCs is not due to inefficient knockdown or
major differences in expression. Moreover, PHF5A ex-
pression levels were similar in GSCs, NSCs, and other
tissues, indicating that GSCs do not abnormally over-
express the gene (Supplemental Fig. S1c). We further
performed a complementation assay in which a validated,
inducible shPHF5A sequence targeting the PHF5A en-
dogenous 39 untranslated region (UTR) was coexpressed
with the PHF5A ORF lacking its endogenous 39 UTR.
Expression of the PHF5A ORF rescued the growth defect
observed in PHF5A knockdown GSCs (Fig. 1F; Supple-
mental Fig. S1d), indicating that the phenotypic effects
are PHF5A-specific.
Furthermore, to query what key roles PHF5A might
play in our cells, we examined PHF5A-interacting pro-
teins by coimmunoprecipitation (co-IP) mass spectrom-
etry. This yielded a strong enrichment for candidate
interacting proteins involved in splicing (GO:0008380
RNA splicing, P = 1014) as well as gene expression (GO:
0010467 gene expression, P = 1016) (Fig. 1G; Supple-
mental Table S1).
PHF5A is specifically required for normal exon
recognition in GSCs but not NSCs
Because PHF5A has been characterized as both a splicing
factor (Will et al. 2002; Rzymski et al. 2008) and a tran-
scriptional regulator (Oltra et al. 2003), we next wished to
define which of these activities was most relevant for
GBM-specific survival. Recently, Paulsen et al. (2009)
found that knockdown of multiple spliceosomal genes in
HeLa cells resulted in dsDNA breaks and H2AX phos-
phorylation. We therefore first examined whether PHF5A
knockdown might similarly give rise to DNA damage in
GSCs, thereby triggering arrest and growth inhibition.
However, upon PHF5A knockdown in GSCs, we did not
see an increase in pH2AX levels, phosphorylation of the
DNA damage signaling proteins CHK1 and CHK2, or
activation of the mitotic spindle checkpoint (Supplemen-
tal Fig. S2a). These results suggest that the shPHF5A
growth inhibition does not simply arise from a DNA
damage response or alterations in the mitotic spindle.
We next hypothesized that PHF5A knockdown might
induce GSC-specific aberrant splicing of genes required
for cell cycle progression or cell growth. To directly test
this hypothesis, we asked whether splicing was globally
dysregulated following PHF5A knockdown by perform-
ing deep RNA sequencing (RNA-seq) in control NSCs
(CB660 cells) and GSCs (G166 and 0827 cells) treated
with control or PHF5A-targeting shRNAs. We quantified
changes in isoform ratios using only reads that crossed
splice sites, an approach that treats all splicing events
with equivalent statistical power (Bradley et al. 2012).
This analysis revealed that PHF5A knockdown results
in dramatic GSC-specific exon skipping and intron reten-
tion events (Figs. 2A; Supplemental Fig. S2b) in hundreds
of genes. Other forms of splicing regulation, including
selection of competing 59 and 39 splice sites and mutually
exclusive exon selection, were unaffected (Supplemental
Fig. S2b) in both GSCs and NSCs. Most of the resulting
GSC-specific splicing changes introduced in-frame stop
codons into the mRNAs, strongly suggesting that the
splicing changes are aberrant, rather than functionally
relevant, splicing (Fig. 2B). Furthermore, the overall ex-
pression of GSC mRNAs harboring in-frame stop co-
dons was decreased, consistent with triggering nonsense-
mediated mRNA decay (NMD) (Fig. 2B; Amrani et al.
2006).
Only a relatively small subset of splice junctions was
affected by PHF5A depletion in GSCs, indicating that the
requirement for PHF5A is not universal across exons. To
gain mechanistic insight into the origins of the observed
splicing dysregulation, we identified specific features
characteristic of 59 and 39 splice sites susceptible to
PHF5A knockdown in GSCs. We could not detect differ-
ences in the 59 splice site features of affected genes (data
not shown). 39 Splice sites associated with abnormal
splicing of constitutive junctions had slightly shorter,
but otherwise normal, polypyrimidine tracts relative
to unaffected 39 splice sites. In contrast, 39 splice sites
associated with retained constitutive introns had unusual
C-rich tracts (Fig. 2C). The retained constitutive introns
were short (Fig. 2D) and had unusually proximal branch
points (Fig. 2E). While PHF5A is known as a core compo-
nent of the spliceosome, it appears to be most important
for the recognition of an unusual class of exons with
distinctive 39 splice sites. These data suggested that PHF5A
primarily functions to facilitate exon recognition rather
than regulate alternative splicing, which is consistent
with its characterization as a core component of the
spliceosome (Will et al. 2002).
Novel requirement for PHF5A in brain tumors
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Consistent with the GSC-specific growth defect caused
by PHF5A knockdown, we observed severe RNA process-
ing defects in many genes important for cell cycle pro-
gression, including CDC16, CDC20, CDC25C, CDC37,
CDC45, and RCC2, in GSCs (G166 or 0827 cells) but not
NSCs (CB660). For example, the 39-most constitutive
exons of CDC20 (Fig. 3A) and many constitutive exons
in RCC2 (Supplemental Fig. S3a) were frequently skipped
following PHF5A knockdown in GSCs but not in NSCs. In
addition, after PHF5A knockdown, multiple constitutive
exons of the well-characterized RTK/Ras signaling effector
RAF1 and the cancer-associated deacetylase HDAC6 were
skipped in GSCs but not in normal NSCs (Fig. 3B).
To further substantiate these results, we examined
the effects of two candidate small molecule inhibitors
of the U2 snRNP complex: spliceostatin A (SSA) and
sudemycin C1 (SudC1). SSA binds to and inhibits the
U2 snRNP subunit SF3b, which contains PHF5A, resulting
in a reduction in the fidelity of branch point recognition
and a down-regulation of genes important for cell division.
(Kaida et al. 2007; Corrionero et al. 2011). SudC1 shares
the consensus pharmacophore of SSA and pladienolide
(Kotake et al. 2007) and also modulates RNA splicing
(Lagisetti et al. 2008, 2009; Fan et al. 2011). We reasoned
that if the most relevant GSC-specific function of PHF5A
is its function in the splicing activity of the U2 snRNP,
Figure 2. PHF5A is globally required by GSCs for proper recognition of an unusual class of exons. (A) In GSCs but not NSCs, PHF5A
knockdown causes a dramatic increase in missplicing of constitutive junctions (top row) as well as retention of constitutive introns
(bottom row). (B) Many of the splicing changes induced by PHF5A knockdown in GSCs introduce in-frame stop codons, suggesting that
the resulting transcripts will be degraded by NMD. Gene expression values were computed with RSEM (Li and Dewey 2011) and
normalized with the TMM method (Robinson and Oshlack 2010). Confidence intervals indicate the first and third quartiles of
expression. (C) Constitutive junctions that are misspliced following PHF5A knockdown in GSCs (center) have slightly shorter
polypyrimidine tracts than do unaffected constitutive junctions (top); in contrast, retained constitutive introns have unusually C-rich
polypyrimidine tracts (bottom). (D) Retained constitutive introns are much shorter. Plot illustrates the median intron length, and error
bars indicate the standard error estimated by bootstrapping. (E) Retained constitutive introns have branch points that are unusually
proximal to the 39 splice site. Box plots indicate the first and third quartiles of the first upstream AG, a proxy for the branch point
location (Gooding et al. 2006). See also Supplemental Figure S2.
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Figure 3. Loss of PHF5A results in splicing defects in GSCs but not NSCs. (A) Select genes important for cell cycle progression, such as
CDC20, display broad splicing defects following PHF5A knockdown. Plot illustrates the density of RNA-seq reads crossing splice
junctions and was created with IGV (Robinson et al. 2011). Aberrant isoforms lacking constitutive exons appear following knockdown
of PHF5Awith two distinct shRNAs. cDNA base pair sizes indicate the expected product size of each isoform using the cdc20 primers
indicated in C and D. (B) RT–PCR of RNA isoforms of example genes after PHF5A knockdown. PCR products were generated using
primers in the indicated exons of each gene. Arrows indicate splicing products specifically induced in GSCs after PHF5A knockdown.
(C) RT–PCR as in B using RNA from cells treated for 24 h with 0.5, 1, 2, or 4 mM SudC1. (D) qRT–PCR using primers designed to
specifically recognize the splice junctions between consecutive and nonconsecutive exons was performed to determine c-values for
inclusion of potentially skipped exons in HDAC6 identified above. The change in inclusion rate after PHF5A knockdown is presented.
(E) Serial dilutions of GSC lysate with or without PHF5A knockdown were run as Western blots and probed with antibodies specific to
example genes with predicted missplicing events. (F) Western blot of GSCs and NSCs with or without PHF5A knockdown probed for
levels of the frequently misspliced protein HDAC6. See also Supplemental Figure S3.
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then these drugs should show a similar pattern of effects
on RNA splicing in GSCs andNSCs. This was indeed the
case. Treatment of GSCs with SudC1 resulted in dose-
dependent GSC-specific splicing defects (Fig. 3C). Fi-
nally, we compared the changes in inclusion of identified
skipped exons in the example gene HDAC6 after PHF5A
knockdown using quantitative RT–PCR (qRT–PCR) primers
designed to span potential consecutive and noncon-
secutive exon splice junctions in the mature RNA iso-
forms. As predicted by the data above, this quantita-
tively demonstrated greater exclusion of tested exons
from mature RNA transcripts in GSCs compared with
normal NSCs (Fig. 3D).
If these aberrant mRNAs are translated, they would
produce C-terminally truncated proteins. We therefore
investigated the effects of PHF5A knockdown on the
protein levels of these example genes. As predicted, the
protein level of PDGFRA, RAF1, and HDAC6 decreased
in knockdown cells (Fig. 3E,F), likely due to effects of
NMD (Fig. 2B) and altered protein stability. This severe
dysregulation of multiple growth regulatory and essen-
tial cell cycle genes in GSCs, but not NSCs, suggests
that aberrant splicing in GSCs following PHF5A knock-
down may give rise to GBM-specific growth defects and
inviability.
Taken together, these results indicate that PHF5A is
important for proper recognition of a specific, relatively
small class of exons in GSCs. Knockdown of PHF5A
causes defective RNA processing of thousands of genes,
a subset of which are essential for cell cycle progression.
Given the broad splicing dysregulation that we observed,
there are likely to be numerous cellular defects induced
by PHF5A knockdown that contribute to the observed
GSC inviability. This model is consistent with our
observation that multiple methods of inhibiting U2
snRNP activity—including knockdown of other spliceo-
somal genes (below) as well as SudC1 treatment—mimic
the effects of PHF5A knockdown even though these
distinct perturbations are unlikely to lead to identical
defects in RNA processing.
PHF5A-binding partners involved in RNA splicing
are also differentially required by GSCs and, when
inhibited, trigger GSC-specific G2/M cell cycle arrest
Because PHF5A may play multiple cellular roles (Will
et al. 2002; Oltra et al. 2003; Rzymski et al. 2008) and its
cellular functions are poorly characterized, we next
wished to define whether its splicing role was its critical
function in GBM cell survival. To this end, we analyzed
knockdown of two PHF5A-binding partners in the spliceo-
some, U2AF1 and DDX1, which interact with the
PHF5A C-terminal and N-terminal domains, respectively
(Rzymski et al. 2008). U2AF1 is a key member of the U2
snRNP, which is required for RNA branch point recogni-
tion (Kramer 1996; Jurica and Moore 2003), and DDX1 is
an ATP-dependent DEAD-box RNA helicase (Fang et al.
2005). Knockdown of either U2AF1 or DDX1 phenocopied
PHF5A knockdown in GSCs (Fig. 4A). Moreover, a com-
prehensive examination of multiple shRNAs against
PHF5A and U2AF1 in short-term growth assays showed
the same strong trend of requirement of these genes in
GSCs but not NSCs (Fig. 4B). These results suggest that
the PHF5A function most relevant for GSC-specific
viability is associated with its role in splicing and the
U2 snRNP complex. Supporting this hypothesis, our
examination of PHF5A-interacting proteins by co-IP mass
spectrometry yielded a strong enrichment for candidate
interacting proteins involved in splicing, especially the U2
snRNP complex, including U2AF1, U2AF2, and mul-
tiple DDX/DHX helicase family members (Fig. 1G; Sup-
plemental Table S1).
A striking feature of PHF5A depletion in GSCs was
that, preceding widespread GSC cell death, PHF5A
knockdown triggered a dramatic cell cycle arrest that
resembled the rounded-up phenotype of kinesin motor
protein KIF11 knockdown (Sawin et al. 1992), our non-
specific cell-lethal control (Fig. 4C). MPM-2 staining,
indicative of CyclinB/CDK activity, dramatically in-
creased in PHF5A knockdown GSCs, confirming mitotic
arrest (Fig. 4C [inset], D). Moreover, DNA content anal-
ysis showed a pronounced increase in the percentage of
G2/M cells in GSCs, but not NSCs or normal fibroblasts,
with PHF5A knockdown (Fig. 4E).
Further examination of GSC PHF5A knockdown G2/
M-arrested cells showed condensed chromatin and mono-
polar or multipolar spindles (Supplemental Fig. S4a). Along
with high MPM-2 staining and little or no phophos-
phorylated BubR1, this is consistent with a preanaphase
arrest in which the mitotic checkpoint has not been
triggered. Consistent with the requirement for U2snRNP
activity, treatment of GSCs with SSA or SudC1 resulted
in a greater dose-dependent viability loss in GSCs re-
lative to NSCs (Fig. 4F; Supplemental Fig. S4b) and also
resulted in the characteristic cell cycle arrest in GSCs
but not NSCs at doses within this efficacy window
(Fig. 4G).
To better characterize GSC-specific G2/M arrest, we
performed metaphase capture assays in H2B-GFP-ex-
pressing GSCs treated with the proteasome inhibitor
MG132, which arrests mitotic cells at metaphase, block-
ing APCCdc20-dependent degradation of Cyclin B (Lampson
and Kapoor 2005). After overnight exposure to SudC1 or
SSA, cells were treated with MG132 for 2 h. Control cells
displayed proper enrichment for metaphase cells, with
chromosomes aligned along the metaphase plate (Fig. 4H).
However, SSA- or SudC1-treated cells were unable to prop-
erly arrest, further suggesting a premetaphase arrest
(Fig. 4H). Similarly, live-cell imaging of GSC-H2B-GFP
cells treated with SudC1 or SSA showed mitotic arrest
premetaphase (Supplemental Movies 1–3). We also ob-
served that the viability loss in drug-treated GSC cultures
results from the death of previously arrested mitotic cells
and not interphase GSCs, identifying the cancer-specific
mitotic arrest as a causative event in cancer cell death
due to splicing inhibition. A fraction of arrested GSCs
were able to survive by progressing throughmitosis after
arresting, but these cells displayed disorganized, multi-
lobed nuclei and were not observed to successfully divide
again (Supplemental Movies 2, 3).
Hubert et al.
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Figure 4. PHF5A and its binding partners are differentially required for GSC expansion, and their inhibition triggers G2/M cell cycle
arrest in GSCs but not NSCs. (A) Model of PHF5A splicing interactions based on previous research. Knockdown of known PHF5A-
binding partners in the spliceosome recapitulates the PHF5A knockdown phenotype, shown. Bar, 50 mm. (B) Cumulative probability
plot of multiple shRNAs scoring as cell-lethal versus their GSC to NSC viability ratio. (C) Fluorescence microscopy images of GSCs or
NSCs expressing constitutive GFP and PHF5A knockdown or control constructs. (Inset) Immunofluorescent images of phospho-
MPM2, indicative of mitotic activity, in GSCs and NSCs depleted for PHF5A. Bar, 100 mm. (D) Quantification of phospho-MPM2
staining in GSCs and NSCs infected with control or shPHF5A virus. (*) P-value < 0.001; (#) insignificant P-value = 0.5. (E) Cellular DNA
content as measured by DAPI staining and FACS analysis in GSC, NSC, and IMR90 normal fibroblast cultures with or without PHF5A
knockdown. The percentage of cells in each sample with 4n DNA content is shown, indicative of cells that have completed DNA
replication in S phase. (F) Viability of GSCs or NSCs treated with increasing doses of SSA. (*) P-value < 0.0003. (G) Immunofluorescent
images of phospho-MPM2 in GSCs and NSCs treated with SSA or SudC1. (H) Fluorescent and light images of GSCs expressing Histone
2B-GFP fusion protein, which marks DNA. Cells were pretreated with SSA or SudC1 for 22 h before addition of MG132 for an
additional 2 h to arrest dividing cells in metaphase. Circles mark the same cell in corresponding images. See also Supplemental Figure 4
and Supplemental Movies S1–S3.
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Taken together, the above results establish that PHF5A
and U2 snRNP complex activity are differentially re-
quired for GSC viability compared with NSCs, and their
activity is necessary for GSC but not NSC transit through
premetaphase mitosis. Moreover, because treatment of
GSCs with SSA or SudC1 did not affect the timing of
mitoses for several hours after drug treatment (Supplemen-
tal Movies 2, 3), it is unlikely that PHF5A and U2 snRNP
activity are directly required for mitotic progression.
Overexpression of MYC recapitulates GSC sensitivity
to splicing inhibition
We next wished to determine the possible mechanism by
which GSCs become differentially sensitive to inhibition
of PHF5A and U2 snRNP activity. One possibility was
that the process of cellular immortalization or oncogenic
transformation itself resulted in splicing dysregulation.
To test this possibility in the context of our normal NSCs,
we investigated the expression of multiple human genes
known to be involved in cellular transformation (Kendall
et al. 2005) and that mimic pathway aberrations fre-
quently found in GBM (Parsons et al. 2008; The Cancer
Genome Atlas Research Network 2008). Specifically, we
used expression of hTERT, dominant-negative p53DD,
CyclinD1, CDK4R24C (p16-resistant), H-RasV12, and MYC
either alone or in combination in NSC-CB660 cells and
tested the sensitivity of the resulting cell lines to the SF3b
inhibitors pladienolide B (Kotake et al. 2007) and SudC1.
That the p53 pathway (i.e., p53DD) and the Rb axis (i.e.,
CyclinD1 and CDK4R24C) were functionally impacted was
noted by virtue of the fact that only combined expression of
p53DD, CyclinD1, and CDK4R24C was sufficient to bypass
RasV12-induced senescence in human NSCs (Supple-
mental Fig. S5a; data not shown).
Using this platform, we found that expression of MYC
alone in NSCs is sufficient to induce sensitivity to
U2snRNP perturbation observed in primary GSC cultures
Figure 5. MYC expression in NSCs recapitulates GSC sensitivity to splicing inhibition. (A) Viability of NSCs with or without
expression of hTERT, p53DD, CyclinD1, CDK4R24C, and/or MYC after treatment with pladienolide B. (B) Viability of NSCs with or
without MYC expression after treatment with SudC1 (top X-axis) or pladienolide B (bottom X-axis). (C) Micrographs of normal CB660
NSCs with or without MYC expression after treatment with the indicated splicing inhibitors. Bar, 64 mm. (D) Log graph of MYC levels
in GSCs and NSCs as determined by RNA-seq (fragments per kilobase of exon per million reads mapped [FPKM] normalized; n = 3)
(Ding et al. 2013). P-values were determined by Student’s t-test. See also Supplemental Figures S5 and S6.
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(Fig. 5A,B). In each experiment, dramatic cell death was
observed at doses not lethal to the parent CB660 cells (Fig.
5C). We further validated this effect in fibroblasts (Sup-
plemental Fig. S5d) and also using two NSC lines immor-
talized through MYC expression (CX and VM) (Donato
et al. 2007) versus two primary NSCs (one embryonic and
one adult-derived) without exogenous MYC (Supplemental
Fig. S5e).Moreover, we observed that ourGSC isolates show
higher expression of MYC mRNA than NSCs (Fig. 5D).
In addition, we found that RasV12 expression alone
could also sensitize NSCs, normal human astrocytes, or
fibroblasts to PHF5A/U2snRNP perturbation (Supple-
mental Figs. S5c,e, S6) but did not synergize with MYC
expression (Supplemental Fig. S5c). Moreover, the acti-
vated MEK allele could partially sensitize cells (Supple-
mental Fig. S5e). Both results are consistent with the
notion that MYC is a downstream target of the Ras path-
way by multiple pathways, including ERK and GSK-3
(Sears et al. 2000). Taken together, these results are
consistent with recent observations regarding brain tu-
mor-associated MYC activity. For example, concomitant
loss of PTEN and p53, two of the most frequently mutated
genes in GBM tumors, activates MYC (Zheng et al.
2008a,b), and MYC activity contributes to maintenance
of tumor-initiating capacity in mouse and human models
of GBM (Wang et al. 2008; Zheng et al. 2008b). The
results suggest that inappropriate MYC activity in GBM
tumors can give rise to molecular vulnerabilities in
PHF5/U2snRNP function. However, future work will
need to determine just how MYC function can impact
the integrity of 39 splice site recognition. However, these
results raise the possibility that a wide range of MYC-
and/or Ras-driven cancer may be vulnerable to PHF5A/
U2snRNP inhibition.
Suppression of PHF5A expression compromises GBM
tumor formation and maintenance in vivo
Finally, we wished to test whether PHF5A expression was
required for GBM tumor formation and maintenance in
vivo. To examine tumor formation, we devised an in vivo
competition experiment to directly test the proliferative
effects of PHF5A suppression in an orthotopic xenograft
model of glioblastoma. GSCs were infected with GFP-
expressing shPHF5A or shCtrl virus and then mixed with
10%ChFP-expressing control cells. This cell mixture was
then either grown in adherent culture or xenografted into
the cortex of immunocompromised mice (Supplemental
Fig. S7a). Whereas shCtrl cells were able to proliferate and
maintain their representation in culture, shPHF5A cells
began to exhibit characteristic cell cycle arrest within
2 d of xenograft and were almost completely replaced by
ChFP+ control cells within 2 wk (Supplemental Fig. S7b).
Likewise, orthotopically xenografted GFP+ shCtrl GSCs
were able to proliferate in vivo, whereas GFP+ shPHF5A
GSCs were unable to proliferate and meaningfully con-
tribute to in vivo tumor growth (Fig. 6A). The small
fraction of coinjected ChFP+ control GSCs were able to
engraft and give rise to tumors in every case, and ChFP
expression mirrored bulk tumor mass as marked by the
Chlorotoxin:Cy5.5 conjugate Tumor Paint (CTX:Cy5.5)
(Veiseh et al. 2007). This underscores that expression of
PHF5A shRNA was the key determinant in whether
GSCs could contribute to tumor growth.
We next wished to examine whether PHF5A inhibition
in established tumors could compromise tumor mainte-
nance, a key metric in evaluating potential therapeutic
avenues. To this end, we generated xenograft mice
bearing GSC tumors with doxycycline (Dox)-inducible
PHF5A shRNA (Fig. 1F; Supplemental Fig. S1d) or control
shRNAs. Tumors were allowed to grow to ;75 mm3 in
size prior to the start of continuous Dox treatment.
Whereas control shRNA tumors showed no measurable
difference in growth rate upon Dox treatment (Fig. 6B),
shPHF5A tumor growth arrested upon Dox administra-
tion, and tumors diminished until they were nearly un-
detectable (Fig. 6C). The onset of this growth arrest cor-
responded to greatly increased phosphorylation of Histone
H3-S10 (Supplemental Fig. S7c,d) indicating a G2/M cell
cycle arrest similar to that seen in vitro for shPHF5A-
treated GSCs.
Since the above tumor studies were carried out in
mouse flanks rather than the brain where GBM arises,
we finally asked whether brain-derived, GSC-driven tu-
mors would respond to PHF5A suppression as well. To
test this, we xenografted GSCs bearing Dox-inducible
PHF5A shRNA into the right cortex of immunocompro-
mised mice. After 52 d, the first mouse showed initial
mild symptoms of a brain tumor. CTX:Cy5.5 imaging
after sacrifice confirmed a tumor signal in the right cortex
(Fig. 6D, inset). We therefore randomized the remaining
mice into Dox-treated and vehicle control cohorts and
followed their survival over time. Survival was signifi-
cantly improved by PHF5A suppression in the Dox-
treated cohort (P = 0.0006), to the point where, at the
conclusion of the study, when all vehicle-treated mice
had succumbed to their tumors, 100% of Dox-treated
mice were alive and free of symptoms (Fig. 6D). We
conclude that PHF5A inhibition compromises both
GBM tumor formation and maintenance, suggesting that
PHF5A/U2snRNP inhibition may be an effective therapy
for GBM.
Discussion
Here, we performed parallel shRNA screens during in
vitro expansion of human GSCs and NSCs to identify
novel gene activities required for growth and viability of
patient-derived GSCs but not normal NSCs. Despite
observing a high degree of GSC isolate-specific variation
in the screening results, we identified PHF5A as differen-
tially required for expansion of all GSCs examined.
PHF5A is a highly conserved PHD-zinc finger domain
protein that facilitates interactions between the U2
snRNP complex and ATP-dependent helicases (Rzymski
et al. 2008). In vitro assays established that PHF5A ac-
tivity was required for G2/M progression in GSCs but not
NSCs. Consistent with a role in GSC-specific splicing
phenomena, knockdown of other U2 snRNP complex
members or pharmacological inhibition of U2 snRNP
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activity both phenocopied PHF5A knockdown. Further-
more, PHF5A knockdown triggered defective splicing of
thousands of essential genes, including many important
for mitotic progression (e.g., CDC20). Examination of
affected splice sites revealed a specific requirement for
PHF5A in recognition of 39 splice sites with C-rich
polypyrimidine tracts in GSCs. Moreover, modeling ex-
periments in MYC- and RasV12-expressing NSCs and
fibroblasts suggested that oncogenic signaling gives rise
to the added requirement for PHF5A and U2 snRNP
activity. Finally, in vivo tumor experiments suggested
that PHF5A is required for generation and, more impor-
tantly, maintenance of GBM tumors. Taken together, our
results support a model whereby oncogenic signaling lead-
ing to increased MYC activity triggers enhanced reliance
on PHF5A/U2snRNP to properly recognize a subclass
of 39 splice sites.
Our results provide new insight into cancer-specific
RNA splicing phenomena. Oncogene-associated activi-
ties (e.g., MYC, AKT, and Ras) can alter splicing of select
genes, including pyruvate kinase (Clower et al. 2010;
David et al. 2010), caspases (Shultz et al. 2010), and CD44
Figure 6. Suppression of PHF5A expression compromises GBM tumor formation and maintenance in vivo. (A) Fluorescence overlay
images of in vivo competition mouse brains 5 wk after xenograft. In addition to GFP and ChFP signal, CTX:Cy5.5 (Tumor Paint) was
used to mark total tumor mass. (B,C) Flank xenograft volume over time of GSC-0131 clones expressing Dox-inducible PHF5A shRNA
or control (Ctrl) shRNA. Tumors were allowed to progress in the absence of Dox until the tumor volume of each cohort averaged;75 mm3.
Mice were then randomized onto continuous Dox or vehicle treatment, and tumor volume was monitored over time. (D) Kaplan-Meier
analysis of mice bearing brain xenografts of Dox-inducible PHF5A knockdown GSCs. (Inset) At the first sign of symptoms in the first
mouse (day 52; CTX:Cy5.5 image) mice were randomized onto continuous Dox or vehicle treatment, and survival was monitored over
time. Photographs of representative mice from each cohort are shown. See also Supplemental Figure S7.
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(Weg-Remers et al. 2001), to promote tumor formation or
growth. Our results provide two important contrasts to
these findings. First, while previous examples of cancer-
associated splicing events can be largely explained by the
activity of canonical splicing regulators on individual
substrates, our results indicate that fundamental aspects
of 39 splice site recognition are modulated by transforma-
tion. In particular, the GSC-specific reliance on PHF5A
suggests that basal spliceosome composition may differ
between normal and transformed cells. Therefore, many
cancer-associated changes in splicing may be inherently
global, rather than specific, phenomena. Second, the
many reports of cancer-promoting protein isoforms sug-
gest that splicing can confer tumor robustness. However,
our findings suggest a different model, wherein splicing is
a source of tumor vulnerability due to ‘‘fragile’’ recogni-
tion of specific subclasses of exons.
Future studies are required to define just how this
vulnerability might arise in GBM and other transformed
cells. One possibility is that oncogenic signaling leads to
direct perturbation of U2 snRNP activity by affecting
complex assembly, activity, turnover, nuclear localiza-
tion, and/or coordination with transcription (for review,
see Heyd and Lynch 2011). As many splicing factors have
complementary or compensatory activity and also par-
ticipate in feedback loops to maintain cellular homeosta-
sis, one attractive model is that transformation disrupts
expression of spliceosomal proteins that normally com-
plement PHF5A’s role. A related question is how MYC
activity gives rise to PHF5A/U2snRNP sensitivity. MYC
is known to affect the expression of specific splicing
factors (David et al. 2010; Das et al. 2012), which can
alter ratios of spliced isoforms of genes such as pyruvate
kinase (David et al. 2010). However, with regard to 39
splice site recognition and U2snRNP function, it is un-
clear whether MYC activity has a direct role in causing
a perturbation or does so indirectly, for example, by
perturbing regulatory pathways that in turn might affect
splicing fidelity (e.g., protein turnover/degradation).
Another key question arising from our studies is whether
PHF5A and U2 snRNP represent reasonable therapeutic
targets for GBM. One notable benefit of targeting their
activity is that partial inhibition simultaneously affects
the splicing of thousands of essential genes. For the vast
majority of affected genes, the resulting isoforms contain
in-frame stop codons, resulting in either degradation by
NMD or translation of aberrant truncated proteins.
Therefore, targeting PHF5A or U2 snRNP leads to partial
or complete loss of function for many essential genes,
collectively causing loss of viability. For example, the
observed arrest phenotype is likely due to simultaneous
dysregulation of many genes required for cell cycle pro-
gression (CDC16, CDC20, CDC25C, CDC37, CDC45,
RCC2, etc.) rather than abrogation of a single ‘‘target’’
gene’s activity. In contrast to the yeast cef1-13 example—
where the arrest phenotype was rescued by removal
of a single misspliced intron in a-tubulin (Burns et al.
2002)—mutations affecting just one of the thousands of
dysregulated splice sites are highly unlikely to rescue
GSCs. As a result, targeting PHF5A/U2 snRNP may have
an advantage over current targeted therapeutic strategies
focused on inhibiting the activities of single oncogenic
drivers (e.g., EGFR, RAF1, AKT, etc.), which cancer cells
can circumvent through mutation or up-regulation of
parallel or downstream pathway components. Moreover,
classes of synthetic and natural compounds already exist
that inhibit U2 snRNP activity (e.g., Pladienolide B,
SudC1, and SSA). The natural product splicing modula-
tors were originally identified on the basis of anti-cancer
activity in vitro and in vivo (Nakajima et al. 1996; Mizui
et al. 2004; Kaida et al. 2007; Kotake et al. 2007), and at
least one derivative has entered clinical trials for solid
tumors (NCT00499499). Our results suggest that further
investigation of this family of compounds may be bene-
ficial for GBM as well as a variety of other MYC- and Ras-
driven cancers.
In summary, this study establishes that patient-derived
GSCs are vulnerable to perturbation in recognition of
a subclass of 39 splice sites, which results in a reduction in
GSC viability and loss of GBM tumor maintenance. Since
standard of care therapies are ineffective against GBM, we
proffer that targeting PHF5A and/or U2 snRNP activity
may offer a new therapeutic inroad for this cancer.
Materials and methods
Pooled shRNA barcode screens and analysis
For both the focused and genome-wide RNAi screens, GSCs or
NSCs were infected with pooled GIPZ lentivirus (Open Biosys-
tems) at a multiplicity of infection (MOI) <1 and selected with
puromycin (Sigma) to remove uninfected cells. Cells were prop-
agated in culture for an additional 21 d, during which time a
minimal representation of 1000-fold per replicate was main-
tained. For each corresponding sample, shRNA barcodes (for
microarray or one-half hairpin for deep shRNA sequencing) were
PCR-recovered from genomic DNA samples. The change in the
relative abundance of each shRNA in the library over time was
measured using the normalized Cy3/Cy5 ratio of its probe signal
or sequence counts. Barcode probes depleted in the GSC samples
were considered candidate screen hits. Hits from the genome-
wide screens were further filtered based on cellular expression as
measured by RNA-seq.
Additional methods can be found in the Supplemental Material.
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